Clinical Trials

Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT06958705 2025-11-25

Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Monotherapy

79 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03128879 2025-11-21

Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL

90 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02827617 2025-11-18

Identification of Biomarkers That Are Predictive of Early Ibrutinib Treatment Failure in High Risk TP53 Mutated Chronic Lymphocytic Leukemia

Completed

56 enrolled

Phase 2 Active not recruiting

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02251548 2025-10-24

iFCR

85 enrolled 17 charts

Phase 1 Active not recruiting

Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02537613 2025-09-30

A Study of Ibrutinib + Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

54 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02315768 2025-09-15

Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients.

Phase 1/2 Completed

32 enrolled 9 charts

Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell

NCT03207555 2025-09-02

Ibrutinib as Early Therapy in Chronic Lymphocytic Leukemia (CLL)

23 enrolled 9 charts

Phase 2 Active not recruiting

Leukemia, Lymphocytic, Chronic, B-Cell

NCT01589302 2025-07-25

PCI-32765 (Ibrutinib) in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-cell Prolymphocytic Leukemia

154 enrolled 18 charts

Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic

NCT02303392 2025-06-10

Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma

Phase 1 Completed

34 enrolled 14 charts

Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT04685915 2025-05-22

Copanlisib Plus Ibrutinib or Acalabrutinib in R/R CLL

Phase 2 Withdrawn

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04781855 2025-02-28

Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter Transformation

Phase 1 Withdrawn

Leukemia, Lymphocytic, Chronic, B-Cell, Hematologic Neoplasms

NCT02388048 2025-01-29

Ofatumumab & Ibrutinib + Allogeneic Bone Marrow Transplant or Consolidation in High Risk Chronic Lymphocytic Leukemia

19 enrolled

Bronchiolitis Obliterans Syndrome, Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02863718 2024-12-30

CLL12

Phase 3 Completed

515 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02950051 2024-12-30

GAIA

Phase 3 Completed

926 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02268851 2024-11-15

A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL

Phase 1 Completed

45 enrolled 13 charts

Phase 1 Active not recruiting

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

NCT03422393 2024-07-05

Venetoclax With High-dose Ibrutinib for CLL Progressing on Single Agent Ibrutinib

24 enrolled

Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Disease Progression

NCT02420912 2024-03-20

Nivolumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or High-Risk Untreated Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Richter Transformation

37 enrolled 12 charts

Chromosome 17 deletion, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02332980 2024-01-03

Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas

65 enrolled 21 charts

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone

NCT05694312 2023-12-01

Ibrutinib for the Treatment of AIHA in Patients With CLL/SLL or CLL-like MBL

Classical hematologyLymphoidOther hematologic neoplasm

45 enrolled

Anemia, Hemolytic, Autoimmune, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02869633 2023-10-23

Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant

23 enrolled 10 charts

Hodgkin Disease, Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

NCT04758975 2023-10-04

VALUABLE

55 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04908228 2023-10-03

FIGHT

53 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02758665 2023-01-17

CLL2-GiVe

41 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03454165 2023-01-04

A Study of BNC105P Combined With Ibrutinib

Phase 1 Completed

6 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03280160 2022-09-16

Protocol GELLC-7: Ibrutinib Followed by Ibrutinib Consolidation in Combination With Ofatumumab

Phase 2 Unknown

84 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04665115 2022-08-03

Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 2019 (COVID-19)

Phase 2 Withdrawn

Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT03045328 2021-09-29

Venetoclax and Ibrutinib in Patients With Relapsed/Refractory CLL or SLL

22 enrolled 14 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02582320 2021-09-13

Clinical-biological Characteristics and Outcome of Chronic Lymphocytic Leukemia Under Ibrutinib-named Patient Program

Completed

264 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04771507 2021-02-25

IbruOnOff

Phase 1/2 Recruiting

50 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03755947 2021-02-02

Ibrutinib, Obinutuzumab and Venetoclax for Patients With Chronic Lymphocytic Leukemia

3 enrolled

Disease, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02689141 2020-06-11

Sequential Regimen of Bendamustin-Debulking Followed by Ofatumumab and Ibrutinib in CLL Patients (CLL2-BIO)

66 enrolled

Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02801578 2020-02-27

A Study of Different Doses of Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)

Phase 2/3 Completed

11 enrolled 7 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT01752426 2020-02-24

Pilot Study to Determine Effects of the Btk Inhibitor PCI-32765 on Leukemia Cell Kinetics and Trafficking, Using Heavy Water Labeling in Subjects With CLL and SLL

Phase 1/2 Completed

30 enrolled 9 charts

Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell

NCT04043845 2020-02-05

ERK 1/2 Signaling in Ibrutinib Resistant B-cell Malignancies

Phase 1 Withdrawn

Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT04094051 2019-09-18

Observational Study of CLL/SLL Treatment and Ibrutinib Treatment of CLL/SLL in Routine Clinical Practice

Unknown

580 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02611908 2019-01-25

Obinutuzumab With High-dose Ibrutinib for the Treatment of Patients With Chronic Lymphocytic Leukemia With Progressive Disease on Single Agent Ibrutinib.

Phase 1 Withdrawn

Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02991638 2018-04-12

Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers

Phase 3 Unknown

62 enrolled

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Hepatitis B, Chronic, Lymphoma, Mantle-Cell

NCT02200848 2018-01-12

Phase I Study of Lenalidomide, Rituximab and Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Phase 1 Terminated

5 enrolled